Handa Oncology Receives FDA Tentative Approval for OMCAZIO (cabozantinib) Capsules

A novel 505(b)(2) alternate-salt formulation of cabozantinib designed to improve absorption, with no clinically significant food effect TAIPEI, TW / ACCESS Newswire / July 31, 2026 / Handa Pharmaceuticals, Inc. ("Handa") (TSE:6620) announced that …